Journal of Drugs in Dermatology最新文献

Socioeconomic Disparities in Gentle Skin Care Access for Atopic Dermatitis: Affordability and Pharmacy Deserts. 特应性皮炎温和皮肤护理的社会经济差异：可负担性和药房沙漠。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-07-01 DOI: 10.36849/JDD.8911

Stephanie Cardenas, Natalia N Khosla, Michelle Verghese, Karina Grullon, Dima Kenj Halabi, Adena E Rosenblatt

{"title":"Socioeconomic Disparities in Gentle Skin Care Access for Atopic Dermatitis: Affordability and Pharmacy Deserts.","authors":"Stephanie Cardenas, Natalia N Khosla, Michelle Verghese, Karina Grullon, Dima Kenj Halabi, Adena E Rosenblatt","doi":"10.36849/JDD.8911","DOIUrl":"https://doi.org/10.36849/JDD.8911","url":null,"abstract":"Background: Gentle skin care is key to atopic dermatitis (AD) treatment, yet products are often expensive. Pharmacy deserts may exacerbate socioeconomic disparities in AD.Objective: To compare the price of dermatologist-recommended skin care to popularly purchased products, and to assess the prevalence and accessibility of pharmacy retailers selling these products in low- versus high-income zip codes.Results: National Eczema Association (NEA)-recommended products were more expensive than popularly purchased products for moisturizing lotions ($2.72/oz vs $1.13/oz, P<0.0001) and liquid body soaps ($1.30/oz vs $0.35/oz, P<0.0001) across all retailers (Amazon, Walmart, Walgreens, CVS, Target, and Meijer). Lower-income zip codes had significantly lower densities of retail stores than higher-income zip codes in both Chicago (0.26 vs 3.20 stores/10,000 pop, P=0.0007) and New York (0.26 vs 2.90 stores/10,000 pop, P=0.02). Stores in low-income zip codes had fewer hours of operation in both Chicago (14.9 vs 19.2 hours/day, P=0.02) and New York (13.3 vs 21.0 hour/day, P=0.0002) and lower stock in both Chicago (2.0 vs 5.1 units, P=0.05) and New York (1.4 vs 4.8 units, P=0.03).Conclusions: Recommended products are more expensive than popular products. Retail pharmacies selling these products are less prevalent in low-income neighborhoods, have fewer hours of operation, and have lower average stock, exacerbating AD disparities.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 7","pages":"683-686"},"PeriodicalIF":1.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alopecia Areata in Skin of Color: Trichoscopic Analysis in Black/African American Patients. 有色皮肤斑秃：黑人/非裔美国人患者的毛发镜分析。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-07-01 DOI: 10.36849/JDD.9139

Josephine Pyles, Victoria Palmer, Emily Balding, Jorge Larrondo, Amy McMichael

{"title":"Alopecia Areata in Skin of Color: Trichoscopic Analysis in Black/African American Patients.","authors":"Josephine Pyles, Victoria Palmer, Emily Balding, Jorge Larrondo, Amy McMichael","doi":"10.36849/JDD.9139","DOIUrl":"https://doi.org/10.36849/JDD.9139","url":null,"abstract":"Importance: Alopecia areata (AA) has a higher prevalence in populations with skin of color, yet the trichoscopic features in this population remain underexplored.Objective: To identify trichoscopic findings present in a cohort of Black patients with a diagnosis of alopecia areata.Evidence review: The electronic medical records system was used to retrospectively analyze the trichoscopic images and medical records of 10 Black patients with a clinical diagnosis of AA who were seen and treated at an academic hair loss clinic between 2019 and 2024. Clinical and trichoscopic images of the scalp were reviewed independently by two board-certified dermatologists. Statistical analysis using the Mann-Whitney U Test highlighted significant trends in the occurrence of these features across varying severity levels as per the Severity of Alopecia Tool (SALT) scores.Findings: Commonly reported features such as vellus hairs, black dots, and tapering hairs, alongside novel features including peripilar hyperpigmentation, follicular hypopigmentation, diffuse erythema, uninterrupted honeycomb patterns, and perifollicular scale were observed. No statistical significance was noted between the presence of trichoscopic features and the correlated SALT score.Conclusions and relevance: This study underscores the need for improved understanding and documentation of AA in Black individuals. Identification of trichoscopic features in AA will aid physicians with diagnosis and decrease the threshold for diagnosis of co-existing alopecias.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 7","pages":"708-712"},"PeriodicalIF":1.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multidisciplinary Impact and Ethical Response to Skin Bleaching and Colorism. 皮肤漂白和肤色歧视的多学科影响和伦理反应。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-07-01

Warda Abdi, Travis W Blalock

引用次数: 0

The Use of Biologic Therapeutic Regimens in Cutaneous and Systemic Mastocytosis: A Scoping Review. 生物治疗方案在皮肤和全身肥大细胞增多症中的应用：范围综述。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-07-01 DOI: 10.36849/JDD.8437

Tebyan Khalfalla, Kareena S Garg, S Minhaj Rahman, Aamir N Hussain

{"title":"The Use of Biologic Therapeutic Regimens in Cutaneous and Systemic Mastocytosis: A Scoping Review.","authors":"Tebyan Khalfalla, Kareena S Garg, S Minhaj Rahman, Aamir N Hussain","doi":"10.36849/JDD.8437","DOIUrl":"10.36849/JDD.8437","url":null,"abstract":"Background: Mastocytoses, a category of diseases characterized by the clonal proliferation of mast cells and the release of their mediators, can be broadly classified as systemic mastocytosis (SM), cutaneous mastocytosis (CM), or mast cell sarcoma (MCS), with treatment options and prognoses varying based on subtype. Advancements in biologics and genetic testing have increased the variety of therapeutic options for mastocytoses. This paper characterizes the therapeutic landscape for mastocytoses with a focus on biologics and other novel medications.Methods: A comprehensive literature search of PubMed and Scopus databases was conducted from the inception of the databases to January 31, 2024. Search terms included \"[disease state] AND [biologic class]\" or \"[disease state] AND [biologic name]\".Results: Of the 672 screened articles, 55 met the following inclusion criteria: (1) diagnosis of either CM, SM, or MCS, and (2) treatment with one of the following biologic regimens: tyrosine kinase inhibitor (TKI) (including a JAK/STAT inhibitor (JAK1/2i), or a monoclonal antibody). Treatment led to successful resolution of the disease or reduction of symptoms in 90% of the patients using TKIs (n=698), including all patients (n=4) using the JAK1/2i ruxolitinib alone, and 90.6% (n=125) using monoclonal antibodies.Conclusion: Successful treatment or symptom improvement of SM, CM, and MCS has been demonstrated through the use of JAK1/2i, TKI, and monoclonal antibodies. More studies are needed to characterize JAK1/2i regimens as clinical trials are lacking.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 7","pages":"687-691"},"PeriodicalIF":1.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tirbanibulin 1% Ointment: The Mechanism of Action of a Novel Topical Therapy for Actinic Keratosis. 1%替巴布林软膏：一种新的局部治疗光化性角化病的作用机制。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-07-01 DOI: 10.36849/JDD.19913

Alyssa M Roberts, Leon Kircik, Mark Lebwohl, April W Armstrong

{"title":"Tirbanibulin 1% Ointment: The Mechanism of Action of a Novel Topical Therapy for Actinic Keratosis.","authors":"Alyssa M Roberts, Leon Kircik, Mark Lebwohl, April W Armstrong","doi":"10.36849/JDD.19913","DOIUrl":"10.36849/JDD.19913","url":null,"abstract":"Actinic keratosis (AK) is a common, precancerous skin lesion that may progress to squamous cell carcinoma (SCC). Traditional topical therapies for AKs often require long treatment durations. These therapies may also cause significant local skin reactions that can reduce patient adherence. Tirbanibulin, a first-in-class topical agent for AKs on the face and scalp, was approved by the US Food and Drug Administration (FDA) in 2020. Tirbanibulin serves as a promising alternative with a shorter treatment duration of five days. Unlike other topical AK therapies, tirbanibulin targets microtubules in keratinocytes. The agent inhibits tubulin polymerization, disrupts the microtubule network, and induces cell cycle arrest. These cellular effects may be reversible, reducing tirbanibulin's toxicity profile. Tirbanibulin has also demonstrated antiproliferative activity with the potential to selectively target highly proliferative keratinocytes, contributing to its antitumorigenic effects. In addition, studies suggest that tirbanibulin may induce apoptosis and interfere with the activity of Src, a tyrosine kinase that can contribute to the progression of AKs and SCCs. Tirbanibulin’s shorter treatment duration and favorable safety profile make it an appealing choice in AK management. In clinical studies, tirbanibulin 1% ointment was well-tolerated and demonstrated significant efficacy in clearing AK lesions in areas up to 100 cm2 on the face and scalp. Tirbanibulin's novel mechanism of action introduces a new, exciting option for the field treatment of AKs. J Drugs Dermatol. 2025;24:7(Suppl 1):s13-18.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 7","pages":"19913s13-19913s18"},"PeriodicalIF":1.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tirbanibulin 1% Ointment: Clinical Trial and Real-World Evidence on Efficacy, Tolerability, Safety, and Patient-Reported Outcomes. 1%替巴布林软膏：关于疗效、耐受性、安全性和患者报告结果的临床试验和真实世界证据。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-07-01 DOI: 10.36849/JDD.19912

Charlotte Jeong, Leon Kircik, Mark Lebwohl, April W Armstrong

引用次数: 0

Treating Chronic Hand Eczema with Upadacitinib: Insights from Clinical Trials and Real-World Experience. 用Upadacitinib治疗慢性手部湿疹：来自临床试验和现实世界经验的见解。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-07-01 DOI: 10.36849/JDD.9156

Omar Alani, Lara Shqair, Walter J Liszewski, Henry Yu, Iyla Draw, Samer Wahood, Fabrizio Galimberti, Beth Sweney, Sabine Obagi, Andrew Mastro, Diego Dasilva, Christopher G Bunick

{"title":"Treating Chronic Hand Eczema with Upadacitinib: Insights from Clinical Trials and Real-World Experience.","authors":"Omar Alani, Lara Shqair, Walter J Liszewski, Henry Yu, Iyla Draw, Samer Wahood, Fabrizio Galimberti, Beth Sweney, Sabine Obagi, Andrew Mastro, Diego Dasilva, Christopher G Bunick","doi":"10.36849/JDD.9156","DOIUrl":"10.36849/JDD.9156","url":null,"abstract":"Background: Chronic hand eczema (CHE) is a chronic inflammatory skin condition that affects the hands and wrists causing itching, dryness, cracking, and pain. It often affects people with atopic dermatitis (AD) and can interfere with work and daily life. Topical therapies may have limited utility from ineffectiveness, poor adherence, or poor tolerability. Here, we evaluate oral upadacitinib (UPA) as a potential therapeutic alternative for patients with AD and refractory CHE.Methods: This narrative review analyzed studies from PubMed, SCOPUS, and EMBASE evaluating CHE treatments. Eligible studies utilized the Hand Eczema Severity Index (HECSI), a validated clinician-reported outcome measure assessing CHE severity. HECSI-75 is the proportion of patients achieving at least a 75% improvement in clinical severity. Cases of three CHE patients from diverse demographics are presented.Results: In two phase 3 randomized controlled trials of UPA for moderate-to-severe AD, 94.8% (803/847) and 92.6% (774/836) of patients had CHE with HECSI assessments at baseline. Rapid improvement in CHE was observed in patients who received either dose of UPA (15 mg or 30 mg) as early as week 1 (P≤0.001 vs placebo). By week 8, up to 83% of UPA-treated patients achieved a statistically significant improvement in CHE (HECSI 75; P≤0.001 vs placebo). These benefits were sustained through week 16. Real-world clinical cases showed CHE patients experienced marked symptom relief within days of initiating UPA.Conclusion: UPA-treated patients experienced rapid and sustained relief from CHE lesions, making it a promising therapeutic option for CHE patients for whom topical therapies are ineffective.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 7","pages":"702-707"},"PeriodicalIF":1.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Use of Neoadjuvant Hedgehog Inhibitors Among Mohs Surgeons: Results of a Cross-Sectional Survey. 目前在莫氏外科医生中新辅助刺猬抑制剂的使用：一项横断面调查的结果。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-07-01 DOI: 10.36849/JDD.9105

Lauren Gresham, Grant Randall, Jesalyn A Tate

{"title":"Current Use of Neoadjuvant Hedgehog Inhibitors Among Mohs Surgeons: Results of a Cross-Sectional Survey.","authors":"Lauren Gresham, Grant Randall, Jesalyn A Tate","doi":"10.36849/JDD.9105","DOIUrl":"https://doi.org/10.36849/JDD.9105","url":null,"abstract":"Recent studies have demonstrated functional and cosmetic benefits with the use of hedgehog pathway inhibitors in the neoadjuvant setting for basal cell carcinoma (BCC). This study investigated the current use of neoadjuvant therapy by Mohs surgeons for the treatment of BCC with an anonymous REDcap survey distributed to members of the American College of Mohs Surgery. In the study population, a considerable percentage (22%) of Mohs surgeons reported current use of neoadjuvant hedgehog inhibitors for BCC prior to Mohs surgery. Among this group, there is wide variation in BCC size, location, target tumor size reduction, and average length of therapy for their use of neoadjuvant hedgehog inhibitors prior to Mohs surgery. Concerns about adverse effects and creating a discontinuous tumor were the most cited reasons not to treat patients with neoadjuvant hedgehog inhibitors prior to Mohs surgery. Given there is better tolerability of hedgehog pathway inhibitors when used for shorter treatment duration, hedgehog pathway inhibitors may be most useful in the neoadjuvant setting to maximize clinical benefit and minimize toxicity.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 7","pages":"722-723"},"PeriodicalIF":1.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pincer Nail Deformity in an African American Patient Corrected by Fractionated Carbon Dioxide Laser. 分离式二氧化碳激光矫正非裔美国患者钳甲畸形一例。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-07-01 DOI: 10.36849/JDD.8783

Alexia Collins, Margaret Kabakova, Kayla Zafar, Sumer Baroud, Sharon Glick, Jared Jagdeo

引用次数: 0

The Heat Is On: A Review of Heat-Induced Dermatoses. 热来了：热致皮肤病的综述。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-07-01

Savanna I Vidal, Nikita Menta, Adam Friedman

引用次数: 0